The Performance of Multi-tracer Multimodality PET in Lymphoma

Positron-Emission Tomography Clinical Trial

Official title:

The Performance of Multi-tracer Multimodality PET in Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05004961
• Other study ID #: XW-MMPET-001
• Status: Recruiting
• Start date: September 15, 2019
• Est. completion date: December 31, 2023

Study information

• Verified date: March 2023
• Source: Peking University Cancer Hospital & Institute
• Contact: Xuejuan Wang, MD
• Phone: 86 010 88196363
• Email: xuejuan_wang[@]hotmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Investigating the performance of Multi-tracer Multimodality PET in lymphoma

Description:

In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our Previous studies have shown that uptake of FAPI-04 on PET may be an indicator of lymphoma lesions. The combination of PET with CT/MR allows for depicting metabolic, functional and morphological properties of tumor lesions at the same time, which is therefore an alternative attractive pairing for diagnosis, staging and prognosis of lymphoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 31, 2023
• Est. primary completion date: August 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years to 80 Years

Eligibility

Inclusion Criteria:

• pathologically diagnosed as lymphoma;
• Written informed consent for receiving FAPI-04 PET examinations.
• cancer planned chemotherapy or immunotherapy scheme.
• expected survival = 12 weeks

Exclusion Criteria:

• cannot lie supine for half an hour;
• refuse to join the clinical researcher;
• severe liver or kidney dysfunction
• pregnancy or lactation

Related Conditions & MeSH terms

• Lymphoma
• Positron-Emission Tomography

Locations

Country	Name	City	State
China	Peking University Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Cancer Hospital & Institute

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SUVmax	Standardized uptake value of 68Ga/ 18F-NOTA-FAPI 04 for target lesion of subject or suspected tumor in each time point window (SUV)	150 days